<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02674763</url>
  </required_header>
  <id_info>
    <org_study_id>IMGN779 0601</org_study_id>
    <nct_id>NCT02674763</nct_id>
  </id_info>
  <brief_title>Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoGen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunoGen, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multicenter Phase 1 study to determine the MTD, dosing schedule and
      RP2D of IMGN779 when administered as mono-therapy to adult AML patients with CD33 -positive
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the Dose Escalation Phase, patients will be assigned to one of two schedules. The MTD for
      both schedules will be determined from the assessment of Dose Limiting Toxicities (DLTs). The
      Dose Expansion Phase will consist of two cohorts based on patients response to prior therapy
      according to the MTD selected.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of IMGN779</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) (complete response [CR= CR+CRp+CRi]+partial remission [PR])</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: maximum plasma concentration (Cmax) of IMGN779</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: area under the time-concentration curve (AUC) of IMGN779</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: terminal half-life (tÂ½) of IMGN779</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Presence of Antibody-Drug Antibody (ADA)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Schedule A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMGN779 administered on days 1 and 15 of a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Schedule B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMGN779 administered on days 1, 8, 15 and 22 of a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with AML at first relapse occurring within12 months; IMGN779 administered at dose and schedule selected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Relapse Refractory AML; IMGN779 administered at dose and schedule selected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMGN779</intervention_name>
    <arm_group_label>Dose Escalation Schedule A</arm_group_label>
    <arm_group_label>Dose Escalation Schedule B</arm_group_label>
    <arm_group_label>Dose Expansion Cohort 1</arm_group_label>
    <arm_group_label>Dose Expansion Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dose Escalation: Patients with relapsed or refractory AML

          -  Dose Expansion Cohort 1: Patients with relapsed AML or patients who refuse, or ar not
             suitable candidates for induction therapy

          -  Dose Expansion Cohort 2: Patients with refractory AML

        Exclusion Criteria:

          -  Dose Escalation: Acute Promyelocytic Leukemia

          -  Any concurrent anti-cancer therapy including chemotherapy, immunotherapy,
             radiotherapy, biologic or any investigational agents (with the exception of
             hydroxyurea or leukapheresis for control of hyperleukocytosis) within 14 days or five
             half-lives of drugs, whichever is shorter, prior to Cycle 1 Day 1

          -  AML patients with known, active leptomeningeal/central nervous system (CNS)
             involvement

          -  Prior treatment with IMGN779

          -  Women who are pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Zweidler-McKay, MD</last_name>
    <role>Study Director</role>
    <affiliation>ImmunoGen, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ImmunoGen Clinical Operations</last_name>
    <email>IMGN601@immunogen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Comprehensive Cancer Center (UAB CCC)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Erba, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel DeAngelo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Mexico Cancer Care Alliance</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Arana-Yi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eunice Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Knight Cancer Institute - OSHU</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elie Traer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas, MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Cortes, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2016</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>IMGN779</keyword>
  <keyword>ImmunoGen</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>CD33</keyword>
  <keyword>Dose Escalation</keyword>
  <keyword>Dose Expansion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

